10-Q: 3M Reports Mixed Q2 2025 Results Amidst Major Legal Settlements and PFAS Exit Costs

3M's second quarter 2025 GAAP earnings per share declined significantly due to substantial legal settlement charges, while adjusted results showed growth, as the company continues its PFAS manufacturing exit and manages ongoing litigation.

Summary

• Net sales for the second quarter of 2025 increased by 1.4% to $6.344 billion, and for the first six months of 2025, net sales increased by 0.2% to $12.298 billion.
• Organic sales growth was 0.6% for Q2 2025 and 0.2% for the first six months of 2025.
• GAAP operating income for Q2 2025 was $1.140 billion, down from $1.272 billion in Q2 2024, with operating income margin decreasing by 2.3 percentage points to 18.0%.
• GAAP diluted earnings per share (EPS) for Q2 2025 was $1.34, a 38% decrease from $2.07 in Q2 2024.
• Adjusted diluted EPS for Q2 2025 was $2.16, a 12% increase from $1.93 in Q2 2024, excluding special items.
• Cash flows from operating activities for the first six months of 2025 were negative $1.033 billion, a significant decrease from $1.788 billion in the same period last year, primarily due to $3.1 billion in payments for PWS and CAE legal settlements.
• The company recorded a pre-tax charge of $281 million in Q2 2025 related to the New Jersey PFAS Settlement, with expected payments of up to $450 million.
• Total environmental liabilities, primarily PFAS-related, increased by approximately $0.4 billion in the first six months of 2025 to $7.4 billion as of June 30, 2025.
• The company made $1.4 billion in payments related to the Combat Arms Earplugs (CAE) settlement in the first six months of 2025, with an accrued liability of $2.4 billion remaining.
• 3M is progressing towards exiting all PFAS manufacturing by the end of 2025 and discontinuing the use of PFAS across its product portfolio by the end of 2025.
• A new $7.5 billion share repurchase program was authorized in February 2025, with $5.7 billion remaining available as of June 30, 2025.
• The company paid quarterly dividends of $0.73 per share in Q1 and Q2 2025, representing a 4% increase in Q1.
• 3M sold its fused silica business in June 2025 for immaterial proceeds.
• The company maintains a 19.9% ownership interest in Solventum Corporation, valued at $2.6 billion as of June 30, 2025, and intends to divest this interest within five years from the April 2024 spin-off.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to significant GAAP financial declines driven by substantial legal settlement payments and ongoing litigation risks. While adjusted results show underlying business strength and the company is actively managing its portfolio and returning capital, the magnitude of the legal liabilities and the negative operating cash flow present considerable headwinds and uncertainty.

Positives

• Adjusted diluted EPS increased by 12% in Q2 2025 and 11% for the first six months of 2025, indicating underlying business performance improvements when excluding special items.
• Operating income margins, when adjusted for special items, increased year-over-year for both the Safety and Industrial (from 22.6% to 25.8%) and Transportation and Electronics (from 22.3% to 24.6%) business segments in Q2 2025.
• Sales in the Safety and Industrial segment increased by 3.6% in Q2 2025, driven by growth in electrical markets, industrial adhesives and tapes, abrasives, roofing granules, and personal safety.
• The Consumer business segment saw a 0.6% increase in sales in Q2 2025, supported by new product launches, service improvements, and increased investment in advertising and merchandising.
• The company authorized a new $7.5 billion share repurchase program in February 2025, demonstrating a commitment to returning capital to shareholders.
• Dividends were increased by 4% in Q1 2025 to $0.73 per share, continuing a long history of dividend payments.
• The company maintains a strong liquidity profile with proven access to capital markets and no commercial paper outstanding as of June 30, 2025.
• A pre-tax gain of $47 million was realized in Q2 2025 from the sale of an interest in an unconsolidated investment.

Negatives

• GAAP diluted EPS decreased by 38% in Q2 2025 and 2% for the first six months of 2025, primarily due to significant litigation charges and the change in value of Solventum ownership.
• GAAP operating income margin decreased by 2.3 percentage points in Q2 2025, negatively affected by special items, particularly the New Jersey PFAS Settlement.
• Cash flows from operating activities were negative $1.033 billion for the first six months of 2025, largely due to $3.1 billion in payments for PWS and CAE legal settlements.
• Net debt increased by $3.616 billion from December 31, 2024, to $8.916 billion as of June 30, 2025.
• The Transportation and Electronics business segment experienced a 0.6% sales decrease in Q2 2025 and a 3.0% decrease for the first six months of 2025, impacted by headwinds related to PFAS manufactured products and weakness in the automotive OEM business.
• The Consumer business segment experienced soft consumer discretionary spending, partially offsetting growth in home improvement.
• The effective tax rate increased significantly to 26.6% in Q2 2025 (from 14.4% in Q2 2024) and 22.1% for the first six months of 2025 (from 18.1% in H1 2024), due to the tax effect of the change in value of Solventum ownership and application of Pillar Two Model Rules.

Risks

• The company faces substantial liabilities and ongoing litigation related to PFAS (perand polyfluoroalkyl substances), including the PWS Settlement ($10.5B-$12.5B total payments) and the New Jersey Settlement (up to $450M), with potential for future charges substantially in excess of presently recorded liabilities.
• The company's plan to exit all PFAS manufacturing by the end of 2025 and discontinue use across its product portfolio involves risks such as actual timing, costs, ability to complete the exit, potential governmental actions, ability to find acceptable substitutes, and potential litigation.
• Ongoing litigation related to Combat Arms Earplugs (CAE) carries significant financial obligations, with an accrued liability of $2.4 billion as of June 30, 2025, and potential for new litigation despite the settlement.
• Accelerating global regulatory and legislative activities concerning PFAS, including increasingly stringent restrictions and lower limits, could lead to material costs for compliance, litigation, and enforcement actions.
• The company is exposed to credit loss in the event of nonperformance by counterparties in derivative contracts, although risk is limited to fair value and counterparties are major international banks.
• Fluctuations in foreign currency exchange rates can materially adversely impact the company's results of operations and ability to realize projected growth rates.
• The company's results are affected by competitive conditions and customer preferences, including the timing and market acceptance of new products and changes in customer demand.
• Vulnerability to fluctuations in costs and availability of purchased components, raw materials, energy, and labor due to shortages, increased demand, supply chain interruptions, and regulatory developments.
• Network disruptions, security and data breaches, cyberattacks, and other cybersecurity incidents could disrupt operations, compromise information, and expose the company to expenses and liabilities.
• Acquisitions, strategic alliances, and divestitures, including the Solventum spin-off, carry risks such as integration difficulties, unexpected liabilities, and potential impacts on relationships with stakeholders.
• Operational execution risks, including organizational restructurings and the ability to realize planned productivity improvements, could negatively impact sales, employee relationships, and customer service.
• Defined benefit pension and postretirement plans are subject to financial market risks, which could increase funding obligations.
• Changes in the company's credit ratings or increases in benchmark interest rates could increase the cost of funding.
• Changes in tax rates, laws, or regulations, including international tax reform (OECD Pillar Two Model Rules), could adversely impact financial results.

Future Outlook

The company expects to continue investing in its business to drive organic growth, including research and development, capital expenditures, and commercialization capabilities. It also plans to actively manage its portfolio through acquisitions and divestitures and continue returning cash to shareholders through dividends and share repurchases. Capital spending for 2025 is expected to be approximately $1.0 billion. The company intends to divest its 19.9% ownership interest in Solventum within five years from the April 2024 spin-off. The company is progressing toward exiting all PFAS manufacturing by the end of 2025 and discontinuing the use of PFAS across its product portfolio by the end of 2025, while acknowledging that some third-party PFAS-containing products may continue to be used beyond 2025 in certain applications.

Management Comments

• "Net sales change was driven by strength in electronics, general industrial, and safety end markets partially offset by known softness in auto and auto aftermarket, while consumer remained soft."
• "GAAP operating margins were negatively affected by the YoY impact of special items (primarily an increase in net costs for significant litigation from the second quarter 2025 PFAS-related New Jersey Settlement, discussed in Note 17, and manufactured PFAS products)."
• "Both GAAP and adjusted operating margins reflect benefits from growth, productivity (outside of special items) and lower restructuring costs, partially offset by growth investments, as well as foreign currency and gross tariff impacts."
• "Both GAAP and adjusted EPS reflects growth and productivity (outside of special items) and lower restructuring costs, a second quarter 2025 gain on the sale of an investment (see the Income from Unconsolidated Subsidiaries, Net of Taxes discussion below), and the impact of lower share count."
• "The strength and stability of 3Ms business model and strong free cash flow capability, together with proven capital markets access, provide financial flexibility to deploy capital in accordance with the Company's stated priorities and meet needs associated with contractual commitments and other obligations."
• "Investing in 3Ms business to drive organic growth and deliver strong returns on invested capital remains the first priority for capital deployment."
• "3M expects to continue returning cash to shareholders through dividends and share repurchases."
• "3M believes it will have continuous access to the commercial paper market."
• "The Company will continue to invest in its operations to drive growth, including continual review of acquisition opportunities."

Industry Context

3M's performance reflects broader industry trends, with strength in electronics, general industrial, and safety end markets, while facing softness in the automotive and automotive aftermarket sectors. The ongoing exit from PFAS manufacturing and use across its product portfolio positions 3M to align with accelerating global regulatory trends towards stricter environmental standards for these compounds. The significant legal settlements, particularly related to PFAS and AFFF, highlight the increasing financial and reputational pressures on companies with historical involvement in these chemistries, a trend observed across various industries globally.

Corporate Governance

Legal Proceedings

• Respirator Mask/Asbestos Litigation: Approximately 3,500 individual claimants, with an accrual of $474 million as of June 30, 2025. The State of West Virginia's lawsuit, seeking substantial damages and civil penalties, had an initial bench trial begin in January 2025 and is scheduled to resume in August 2025; no liability has been recorded as it is not probable or estimable.
• Aearo Technologies Respirator Mask/Asbestos Litigation: Accruals of $53 million as of June 30, 2025, for product liabilities and defense costs related to current and future Aearo-related asbestos, silica-related, and coal mine dust claims.
• PFAS-Related Environmental Matters and Litigation: The company faces numerous lawsuits and regulatory actions globally related to PFAS contamination, including increasingly stringent regulations and potential material costs for compliance and remediation.
• New Jersey PFAS Settlement: A proposed Judicial Consent Order with the State of New Jersey was agreed upon in May 2025, resolving statewide PFAS claims for up to $450 million, resulting in a $281 million pre-tax charge in Q2 2025.
• Aqueous Film Forming Foam (AFFF) Litigation: Over 7,800 lawsuits pending, with the PWS Settlement (June 2023) resolving public water supplier claims for $10.5 billion to $12.5 billion. The first personal injury bellwether trial is set for October 20, 2025.
• Combat Arms Earplugs (CAE) Litigation: A settlement arrangement (August 2023) intends to resolve all litigation for up to $6.0 billion, with over 99% claimant participation. An accrued liability of $2.4 billion remained as of June 30, 2025.
• International PFAS Litigation: Includes 18 civil actions and pre-litigation notices in Belgium, a notice of liability from the Netherlands government, and multiple putative class actions in Canada and Australia related to PFAS contamination.
• U.S. Federal PFAS Regulatory Activity: EPA designated PFOA and PFOS as CERCLA hazardous substances, proposed RCRA rules, and issued new drinking water standards, which are subject to legal challenges and could require additional investigative and remediation activities.
• U.S. State PFAS Regulatory and Litigation Activity: Various states are enacting laws and pursuing litigation related to PFAS, including new product restrictions and drinking water standards, which could impose additional financial and remedial obligations.
• Decatur, Alabama Grand Jury Matter: Ongoing cooperation with the U.S. Attorneys Office regarding compliance with a 2009 TSCA consent order and unpermitted discharges to the Tennessee River.
• NPDES Permit Issues: Ongoing engagement with EPA and state environmental agencies (ADEM, IEPA, MPCA) regarding uncharacterized PFAS discharges and permit modifications at Decatur, Cordova, and Cottage Grove facilities.
• Minnesota 2018 Natural Resources Defense Settlement: Ongoing mediation with MPCA regarding disagreements over project reasonableness and long-term operation and maintenance expenses related to the $897 million settlement fund.
• Prairie du Chien, Wisconsin Incident: An employee fatality in May 2023 led to OSHA citations and a grand jury subpoena, with a settlement agreement reached with OSHA in September 2024 for an immaterial payment.
• Lower Passaic River, New Jersey: The company is a defendant in a cost recovery and contribution lawsuit seeking cleanup costs for river contamination.

Related Party Transactions

• 3M has continuing involvement with Solventum Corporation following its April 1, 2024 separation, including net sales under supply agreements and income from transition agreements. Amounts due from Solventum were approximately $0.4 billion and amounts due to Solventum were approximately $0.2 billion as of June 30, 2025.

Stakeholder Impact

• Shareholders: Impacted by significant legal charges reducing GAAP EPS, but also benefit from adjusted EPS growth, a new share repurchase program, and increased dividends. The Solventum spin-off and planned divestiture of the remaining stake will also affect shareholder value.
• Employees: Affected by structural reorganization actions impacting approximately 8,000 positions worldwide since 2023, and PFAS exit restructuring actions impacting approximately 1,200 positions worldwide since 2023. An employee fatality at a facility led to investigations and a settlement.
• Customers: Potential for supply disruptions due to the ongoing exit of PFAS manufacturing and the need to transition to non-PFAS alternatives in products. Continued investment in R&D and commercial excellence aims to support customer needs.
• Suppliers: The company's PFAS exit strategy involves evaluating the availability and feasibility of third-party products that do not contain PFAS, potentially shifting supply chain relationships.
• Creditors: The company's credit ratings and cost of funding are influenced by its debt levels and ongoing legal liabilities, though it maintains strong investment grade ratings and access to capital markets.
• Communities: Impacted by environmental remediation efforts related to PFAS contamination, particularly in areas near manufacturing facilities (e.g., Alabama, Belgium, Minnesota, Wisconsin), and potential benefits from legal settlements aimed at improving drinking water quality.

Next Steps

• Continue to make payments for the PWS Settlement from 2024 through 2036.
• Continue to make payments for the CAE Settlement from 2023 through 2029.
• Begin payments for the New Jersey Settlement starting in 2026 over 8 years, and for existing/future PFAS-related claims from 2030 through 2050.
• Resume the bench trial for the State of West Virginia's lawsuit in August 2025.
• Proceed with the first bellwether personal injury trial for AFFF litigation on October 20, 2025.
• Continue product-identification discovery for 15 AFFF-contaminated sites over the next six months.
• Progress towards exiting all PFAS manufacturing by the end of 2025.
• Work to discontinue the use of PFAS across its product portfolio by the end of 2025.
• Continue to evaluate the availability and feasibility of third-party products that do not contain PFAS beyond 2025.
• Submit TSCA reporting rule data by October 13, 2026.
• Continue to invest approximately $1.0 billion in capital spending for 2025.
• Divest the remaining 19.9% ownership interest in Solventum Corporation within five years from the April 2024 spin-off.
• Continue to implement new business systems and solutions, including an enterprise resource planning (ERP) system.
• Continue mediation process under the 2018 Minnesota Natural Resources Defense Settlement to address disagreements with MPCA.

Key Dates

Recommendation

Keywords

3M, MMM, SEC Filing, 10-Q, Quarterly Report, Financial Results, Earnings, Sales, Operating Income, EPS, PFAS, Perand Polyfluoroalkyl Substances, Environmental Liabilities, Litigation, Combat Arms Earplugs, CAE Settlement, PWS Settlement, New Jersey Settlement, Solventum, Spin-off, Divestiture, Share Repurchase, Dividends, Cash Flow, Debt, Regulatory Compliance, Supply Chain, Industrial, Electronics, Consumer Goods